MARKET

AKBA

AKBA

Akebia Therapeut
NASDAQ
1.460
+0.060
+4.29%
Closed 19:58 03/13 EDT
OPEN
1.410
PREV CLOSE
1.400
HIGH
1.520
LOW
1.400
VOLUME
3.75M
TURNOVER
0
52 WEEK HIGH
4.079
52 WEEK LOW
1.140
MARKET CAP
391.10M
P/E (TTM)
-70.1923
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AKBA last week (0309-0313)?
Weekly Report · 8h ago
Weekly Report: what happened at AKBA last week (0302-0306)?
Weekly Report · 03/09 09:47
Akebia Therapeutics Earnings Call: Vafseo Drives Growth
TipRanks · 03/09 00:26
Top Executive Makes Bold Insider Move at Akebia Therapeutics
TipRanks · 03/06 02:02
Akebia Therapeutics to Present at Leerink Partners Global Healthcare Conference
Reuters · 03/03 13:02
Akebia Therapeutics Grants Inducement Stock Options to Five New Hires
Reuters · 03/02 21:06
AKEBIA THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 03/02 21:05
Weekly Report: what happened at AKBA last week (0223-0227)?
Weekly Report · 03/02 09:47
More
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). The Company's development pipeline includes mid-stage rare kidney disease pipeline assets (praliciguat and AKB-097) and early-stage pipeline assets (AKB-9090 and AKB-10108), which are HIF molecules.

Webull offers Akebia Therapeutics Inc stock information, including NASDAQ: AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.